Clinical Trial Update: The Efficacy and Safety of Treatment with Telitacicept in Antineutrophil Cytoplasmic Antibody-associated Nephritis (AAGN) [Phase 1, Phase 2]

View source ↗

Summary

Telitacicept is being studied for ANCA-associated nephritis in Phase 1/Phase 2 trials, with the study currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Antineutrophil Cytoplasmic Antibody -associated Nephritis

Drugs mentioned

• Telitacicept

Snippet

Sponsor: Renmin Hospital of Wuhan University | Conditions: Antineutrophil Cytoplasmic Antibody (ANCA)-associated Nephritis (AAGN) | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING